News

Month Year

Aruvant Announces the European Medicines Agency (EMA) Granted Priority Medicines (PRIME) Designation to ARU-1801 for the Treatment of Sickle Cell Disease

Feb 3, 2021
Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trial

Jan 18, 2021
Aruvant's Data Presented in Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Demonstrates Promise of ARU-1801 as a Potentially Curative Treatment for Sickle Cell Disease

Dec 7, 2020

--Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile--
Aruvant to Participate in SVB Leerink's Biopharma Private Company Connect December 15 to 17

Dec 1, 2020
Aruvant Receives Orphan Designation from European Medicines Agency for Gene Therapy ARU-1801 for Sickle Cell Disease

Nov 16, 2020
Aruvant Announces Updated Data to be Presented in Oral Presentation of ARU-1801 Data at the 62nd American Society of Hematology (ASH) Annual Meeting

Nov 4, 2020

--Ongoing manufacturing improvements shows enhanced efficacy of ARU-1801 for the treatment of sickle cell disease--
Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy

Oct 12, 2020
Aruvant to Present at Investor and Scientific Conferences in October

Sep 29, 2020
One-time Gene Therapy for Sickle Cell Disease

Jun 3, 2020
Aruvant Appoints Dr. Palaniappan as Chief Technology Officer

Jun 1, 2020

--Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than 30 compounds including gene therapies for rare diseases--

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa